RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
PPH is associated with almost 20 per cent of maternal mortality in India
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
The drug is also intended for the treatment of glioblastoma multiforme
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Subscribe To Our Newsletter & Stay Updated
